Holen Sie sich die Stockscreener-App
62.65
1.26%
0.78
Halozyme Therapeutics Inc Aktie (HALO) Neueste Nachrichten
Smart Money: Is Halozyme Therapeutics Inc stock overvalued by current metricsQuarterly Market Summary & High Yield Stock Recommendations - BỘ NỘI VỤ
Halozyme Therapeutics awards performance-based stock units to CEO By Investing.com - Investing.com Canada
Halozyme Approves Stock Grant for CEO Incentive - TipRanks
Halozyme Therapeutics awards performance-based stock units to CEO - Investing.com
(HALO) Movement as an Input in Quant Signal Sets - news.stocktradersdaily.com
Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term - sharewise.com
Halozyme Therapeutics announces proposed offering of $650M of convertible senior notes due 2031 and 2032 - MSN
Marshall Wace LLP Has $20.24 Million Holdings in Halozyme Therapeutics, Inc. $HALO - MarketBeat
2Xideas AG Sells 62,256 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
James Lang elected to Halozyme Therapeutics board of directors By Investing.com - Investing.com Canada
James Lang elected to Halozyme Therapeutics board of directors - Investing.com
Halozyme Elects James Lang to Board of Directors - TipRanks
Halozyme Therapeutics Elects New Board Member - TradingView
Jim Lang elected to Halozyme’s board of directors By Investing.com - Investing.com India
Jim Lang Elected to Halozyme's Board of Directors - Eastern Progress
Halozyme and Quinn Emanuel secure PI against MSD over Keytruda SC - JUVE Patent
Cash per share of Halozyme Therapeutics, Inc. – FWB:RV7 - TradingView
Halozyme wins German injunction blocking Merck’s Keytruda distribution - Indian Pharma Post
Halozyme granted injunction in Germany barring Merck's subcutaneous Keytruda - MSN
Halozyme Therapeutics (HALO): Reassessing Valuation After Strong Year-To-Date Gains And Recent Momentum Slowdown - Yahoo Finance
Norges Bank Makes New Investment in Halozyme Therapeutics, Inc. $HALO - MarketBeat
American Century Companies Inc. Sells 762,886 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
The Healthcare Sector Is Surging. Here's 1 Stock Every Investor Should Have on Their Radar. - Finviz
Why Is Halozyme Therapeutics (HALO) Down 2.2% Since Last Earnings Report? - MSN
Epoch Investment Partners Inc. Sells 195,366 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) Rating Lowered to "Buy" at Wall Street Zen - MarketBeat
Kennedy Capital Management LLC Has $21.60 Million Stake in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) Receives Sell Rating from The Goldman Sachs Group - MarketBeat
Citizens reiterates Market Outperform rating on Halozyme stock amid legal win - Investing.com
Why Halozyme Therapeutics Inc. stock could rally in 20252025 Trade Ideas & Safe Entry Momentum Stock Tips - Newser
Merck suffers a setback over its new Keytruda formulation in Germany - statnews.com
Halozyme Therapeutics Inc RV7 Stock Analysis and ForecastPrice Action Analysis & The Smart Money Is Buying These Picks - earlytimes.in
Halozyme (HALO) Wins Injunction Against Merck in Germany - GuruFocus
How Halozyme Therapeutics Inc. (RV7) stock behaves in tightening cyclesTrade Risk Summary & Expert Curated Trade Setup Alerts - Newser
Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germany - PR Newswire
Halozyme Therapeutics downgraded by Goldman with a new price target - Quantisnow
Goldman Sachs downgrades Halozyme stock to Sell on looming revenue cliff - Investing.com Nigeria
Is Halozyme Therapeutics Inc. stock dividend yield sustainable2025 Support & Resistance & Capital Protection Trading Alerts - Newser
Mackenzie Financial Corp Has $6.16 Million Stock Holdings in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics, Inc. $HALO Stock Holdings Lessened by CW Advisors LLC - MarketBeat
Fisher Asset Management LLC Decreases Stock Position in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Do Halozyme’s (HALO) Upgrades and Deals Justify Insider Sales or Complicate Its Royalty-Driven Story? - Yahoo Finance
Is Halozyme Still Attractive After 2025 Rally and Recent 11% Pullback? - Yahoo Finance
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
What Analysts Now Think Gives Halozyme Therapeutics The Edge Amid Evolving Risks and Rewards - Yahoo Finance
Skandinaviska Enskilda Banken AB publ Sells 16,900 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
Granite Investment Partners LLC Lowers Holdings in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Arrowstreet Capital Limited Partnership Grows Stock Holdings in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Will Halozyme Therapeutics Inc. (RV7) stock test record highs in 2025Weekly Loss Report & Verified Momentum Stock Ideas - Newser
Is Halozyme Therapeutics Inc. (RV7) stock dividend growth reliableMarket Sentiment Report & Real-Time Buy Signal Notifications - Newser
Is Halozyme Therapeutics Inc. (RV7) stock good for long term investingJuly 2025 Earnings & Reliable Entry Point Alerts - Newser
RENAISSANCE GROUP LLC's Halozyme Therapeutics Inc(HALO) Holding History - GuruFocus
Insider Selling: Halozyme Therapeutics (NASDAQ:HALO) Director Sells 829 Shares of Stock - MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) CEO Helen Torley Sells 16,569 Shares - MarketBeat
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):